{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:14:32Z","timestamp":1781550872321,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigated in patients with non-cirrhotic portal hypertension. We hypothesized higher levels in cirrhotic patients with portal hypertension than patients with non-cirrhotic portal hypertension. We investigated sCD163 and sMR levels in patients with portal hypertension due to idiopathic portal hypertension (IPH) and portal vein thrombosis (PVT) in patients <jats:italic>with<\/jats:italic> and <jats:italic>without<\/jats:italic> cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied plasma sCD163 and sMR levels in patients with IPH (<jats:italic>n<\/jats:italic> = 26), non-cirrhotic PVT (<jats:italic>n<\/jats:italic> = 20), patients with cirrhosis <jats:italic>without<\/jats:italic> PVT (<jats:italic>n<\/jats:italic> = 31) and <jats:italic>with<\/jats:italic> PVT (<jats:italic>n<\/jats:italic> = 17), and healthy controls (<jats:italic>n<\/jats:italic> = 15).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median sCD163 concentration was 1.51 (95% CI: 1.24\u20131.83) mg\/L in healthy controls, 1.96 (95% CI: 1.49\u20132.56) in patients with non-cirrhotic PVT and 2.16 (95% CI: 1.75\u20132.66) in patients with IPH. There was no difference between non-cirrhotic PVT patients and healthy controls, whereas IPH patients had significantly higher levels than controls (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). The median sCD163 was significantly higher in the cirrhotic groups compared to the other groups, with a median sCD163 of 6.31 (95% CI: 5.16\u20137.73) in cirrhotics <jats:italic>without<\/jats:italic> PVT and 5.19 (95% CI: 4.18\u20136.46) <jats:italic>with<\/jats:italic> PVT (<jats:italic>P<\/jats:italic> &amp;lt; 0.01, all). Similar differences were observed for sMR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Soluble CD163 and sMR levels are elevated in patients with IPH and patients with cirrhosis, but normal in patients with non-cirrhotic PVT. This suggests that hepatic macrophage activation is more driven by the underlying liver disease with cirrhosis than portal hypertension.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphys.2021.649668","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T09:52:54Z","timestamp":1623405174000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension"],"prefix":"10.3389","volume":"12","author":[{"given":"Nikolaj Worm","family":"\u00d8rntoft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Baiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ferrusquia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Turon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Magaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger Jon","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Garcia-Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gronbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/liv.14466","article-title":"Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.","volume":"40","author":"Bossen","year":"2020","journal-title":"Liver Int."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000315","article-title":"Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.","volume":"12","author":"Bossen","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jvh.12309","article-title":"Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.","volume":"22","author":"Dultz","year":"2015","journal-title":"J Viral. Hepat."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jhep.2020.07.033","article-title":"Macrophage markers and innate immunity in cirrhosis.","volume":"73","author":"Gr\u00f8nb\u00e6k","year":"2020","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/apt.13801","article-title":"Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis.","volume":"44","author":"Gronbaek","year":"","journal-title":"Aliment Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jgh.15125","article-title":"Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.","volume":"36","author":"Gr\u00f8nbaek","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jhep.2015.11.021","article-title":"Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).","volume":"64","author":"Gronbaek","year":"","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2036.2012.05134.x","article-title":"Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.","volume":"36","author":"Gronbaek","year":"2012","journal-title":"Aliment Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/hep.30132","article-title":"Idiopathic Portal Hypertension.","volume":"68","author":"Hernandez-Gea","year":"2018","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00535-004-1493-8","article-title":"Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.","volume":"40","author":"Hiraoka","year":"2005","journal-title":"J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/gut.2010.234542","article-title":"Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.","volume":"60","author":"Holland-Fischer","year":"2011","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.27129","article-title":"Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.","volume":"60","author":"Kazankov","year":"2014","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/liv.13150","article-title":"The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.","volume":"36","author":"Kazankov","year":"2016","journal-title":"Liver. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jgh.12943","article-title":"Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.","volume":"30","author":"Kazankov","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/00365520410005171","article-title":"Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis.","volume":"39","author":"Keiding","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/35051594","article-title":"Identification of the haemoglobin scavenger receptor.","volume":"409","author":"Kristiansen","year":"2001","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/liv.13262","article-title":"The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.","volume":"37","author":"Laursen","year":"2017","journal-title":"Liver Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.","volume":"27","author":"Laursen","year":"2019","journal-title":"J. Viral. Hepat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jgh.13849","article-title":"Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.","volume":"33","author":"Laursen","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1189\/jlb.0512231","article-title":"The mannose receptor.","volume":"92","author":"Martinez-Pomares","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365513.2011.626868","article-title":"Soluble CD163.","volume":"72","author":"Moller","year":"2012","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jhep.2007.05.014","article-title":"Soluble CD163 from activated macrophages predicts mortality in acute liver failure.","volume":"47","author":"Moller","year":"2007","journal-title":"J. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/003655102760145852","article-title":"Characterization of an enzyme-linked immunosorbent assay for soluble CD163.","volume":"62","author":"Moller","year":"2002","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7742-2_40-1","article-title":"Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease","author":"M\u00f8ller","year":"2016","journal-title":"Biomarkers in liver disease"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1136\/gutjnl-2012-304135","article-title":"Hepatic macrophage activation predicts clinical decompensation in chronic liver disease.","volume":"62","author":"Rode","year":"2013","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1515\/cclm-2013-0451","article-title":"soluble form of the macrophage-related mannose receptor (MR\/CD206) is present in human serum and elevated in critical illness.","volume":"52","author":"Rodgaard-Hansen","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/ajg.2014.262","article-title":"Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study.","volume":"109","author":"Sandahl","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189345","article-title":"The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.","volume":"12","author":"Sandahl","year":"2017","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1365-2036.2012.05112.x","article-title":"Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study.","volume":"35","author":"Schouten","year":"","journal-title":"Aliment Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/apt.12049","article-title":"Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.","volume":"36","author":"Schouten","year":"","journal-title":"Aliment Pharmacol. Ther."},{"key":"B31","article-title":"Alcoholic liver disease.","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1002\/hep.26904","article-title":"Idiopathic portal hypertension: natural history and long-term outcome.","volume":"59","author":"Siramolpiwat","year":"2014","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s10620-018-5186-1","article-title":"\u03b2-Blockers Improve Presinusoidal Portal Hypertension.","volume":"63","author":"S\u00f8rensen","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/gut.2011.242560","article-title":"Kupffer cell activation and portal hypertension.","volume":"60","author":"Steib","year":"2011","journal-title":"Gut"},{"key":"B35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/shk.0b013e3181b85934","article-title":"Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase.","volume":"33","author":"Steib","year":"","journal-title":"Shock"},{"key":"B36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2007.03.019","article-title":"Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2).","volume":"47","author":"Steib","year":"2007","journal-title":"J. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/labinvest.2010.60","article-title":"Gerbes AL. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis.","volume":"90","author":"Steib","year":"","journal-title":"Lab. Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.clinre.2013.12.012","article-title":"Non-cirrhotic portal hypertension\u2013concept, diagnosis and clinical management.","volume":"38","author":"Strauss","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2013.01.005","article-title":"Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.","volume":"58","author":"Waidmann","year":"2013","journal-title":"J. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/hep.1840110512","article-title":"Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules.","volume":"11","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis.","volume":"41","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis.","volume":"60","author":"Wiest","year":"2014","journal-title":"J. Hepatol."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.649668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T17:12:49Z","timestamp":1623431569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.649668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":42,"alternative-id":["10.3389\/fphys.2021.649668"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.649668","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"article-number":"649668"}}